TOI — Stock Film
STOCK FILMSCENE 1/11TOI · $5.13
Stock Expert AI presents
TOI
The Oncology Institute, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
The Oncology Institute, Inc. A quick introduction.

On the stock market since 2020, it operates in the world of health and science. It has 641 employees. Now — the numbers.

on the stock market since 2020
641 employees
$512.9M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing, year after year.

Average growth of 25% a year over the last 4 years. Red columns mark years that ended in a loss.

$203M
2021
$252.5M
2022
$324.2M
2023
$393.4M
2024
$502.7M
2025
In the vault right now:
$0
DEBT: $103.7M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
77
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
85
very strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
63
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
47
weak

Clearly below the class average.

PRICE MOMENTUM
85
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Executives are buying stock8/10
WEAK SPOTS
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 53% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 26% a year on average.

2
THE BRIGHT SIDE · 2/3
Sales are holding up

The company sells $502.7M a year; the problem isn’t sales — it’s costs running above that number.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 51 buys and 24 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
The losses continue

A loss of $60.6M against $502.7M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, TOI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: TOI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film